While these findings suggest that Keap1 can exert its tumor suppressive function in a p53- and Lkb1-indpendent manner, the co-occurrence of KEAP1 mutations with STK11, and to a lesser extent TP53, in KRAS-mutant tumors may imply that cancer cells gain additional growth advantage. This evidence concerns the gene KRAS and neoplasm.